LGD-4033

evidence score

sarm

Research Only

184 studies

LigandrolVK5211LGD4033

LGD-4033 (Ligandrol) is a potent oral SARM with Phase I safety data and Phase II trial data for hip fracture recovery (VK5211, 1–2mg/day). Significantly more anabolic than ostarine at milligram doses — 1mg/day in Phase I produced ~1.2kg lean mass gain. Widely used in fitness communities for bulking. Causes robust testosterone suppression even at low doses. Not approved for human use. WADA-prohibited. Among the most detected substances in athlete doping cases.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Phase II

Research Sync

Feb 19, 2026

Dosing

Typical

10 mg

2 mgRange20 mg

FrequencyOnce daily oral

Set height & weight in Settings to see your dose.

Pharmacology

Half-life24–36 hours

Onset1–2 weeks for noticeable strength; 4–6 weeks for body composition

DurationSuppression persists 4–6 weeks post-cycle

Routes

oral

Evidence Score

Level B — Moderate

184 studies indexed · 1 meta-analysis

Scoring Factors

Volume(40%)~45/100

Quality(30%)~44/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

LGD-4033 is currently categorized as a sarm compound.

Evidence is moderate (67/100): promising signal from 184 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

High-affinity selective AR agonist; near-complete receptor occupancy at low doses produces significant muscle anabolism with moderate bone activation

Practical Context

Strongest current signals

Level A: Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review.
Level B: Development and preliminary testing of a secure large language model-based chatbot for brief alcohol counseling in young adults.
Level C: Lipid polymorphism of plant thylakoid membranes. The dynamic exchange model - facts and hypotheses.

Elevated caution signals

1 severe/high side effect flag